DaVita (NYSE:DVA) Beats Q2 CY2026 Sales Expectations But Stock Drops
DaVita Inc. (NYSE:DVA) reported Q2 CY2026 revenue of $3.55 billion, up 5.2% year on year and 1.7% above Wall Street estimates, and non-GAAP EPS of $4.02, 3.6% above consensus. Adjusted operating margin was 17%. Full-year EPS guidance missed, and the stock fell 9.8% to $210.75.
How this was made
The 30-second read
Why it matters
Q2 results beat revenue and adjusted EPS estimates, but the article states full-year EPS guidance missed and the stock dropped 9.8% to $210.75 immediately after reporting, signaling forward expectations were the key swing factor.
Market read
Traders get a fresh earnings datapoint (Q2 beat) plus a forward-looking negative (full-year EPS guidance miss) that explains the immediate selloff.
What to watch
Treatment volume was flat over two years while revenue grew, implying price/mix support; traders may want to monitor whether that pricing tailwind can sustain into the full-year EPS path.
Background
DaVita is a large dialysis provider operating 2,600+ centers in the US and 13 countries, with performance often driven by treatment volumes, pricing, and cost discipline.
Ticker impact
DaVita reported Q2 CY2026 revenue of $3.55B (+5.2% YoY) and adjusted EPS of $4.02, but the stock fell 9.8% to $210.75.
Near-term volatility likely persists as traders reprice the full-year EPS outlook despite the Q2 beat.
The article provides the key datapoints (beat vs consensus, guidance miss, and same-day drop), but it does not quantify the guidance level versus consensus or explain the selloff drivers beyond 'softer quarter' framing.
Market effects
Dialysis providers may see sentiment hinge on forward EPS guidance and pricing versus treatment volume trends, not just quarterly beats.
Primarily US healthcare sentiment, with no explicit cross-region drivers cited.
Limited global spillover; the article is company-specific with no international regulatory or macro catalyst mentioned.
Counterpoint
The Q2 beat plus stable adjusted operating margin (17% in Q2) could indicate the guidance miss is more about pacing than deterioration, supporting a buy-the-dip setup.
Key entities
- public_companyDaVita Inc.
Reported Q2 CY2026 revenue and adjusted EPS, and provided full-year EPS guidance that the article says missed.
